{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-25-000002","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2025-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.087040+00:00","generated_at":"2026-05-28T07:00:30.936385+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Maravai expects 2024 revenue near midpoint of $255M-$265M; President of Nucleic Acid Production departs","bullets":["Preliminary unaudited 2024 revenue expected near midpoint of $255M-$265M guidance range.","Andrew Burch, President of Nucleic Acid Production, position eliminated; last day Jan 16, 2025.","CEO Trey Martin will assume direct responsibility for Nucleic Acid Production segment.","Q4 and full year 2024 earnings release scheduled for Feb 25, 2025 after market close."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-25-000002","json":"https://secwatch.observer/filing/0001823239-25-000002.json","markdown":"https://secwatch.observer/filing/0001823239-25-000002.md","text":"https://secwatch.observer/filing/0001823239-25-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323925000002/0001823239-25-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323925000002/mrvi-20250102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T07:00:30.936385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"333155505d","claim":"Andrew Burch departed as President, Nucleic Acid Production at MARAVAI LIFESCIENCES HOLDINGS, INC..","evidence_excerpt":"On January 2, 2025, the Company notified Andrew Burch, President, Nucleic Acid Production, that it was eliminating his position in order to flatten the organizational structure of its leadership team. As a result, Mr. Burch’s last day of employment with the Company will be January 16, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323925000002/0001823239-25-000002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"President, Nucleic Acid Production"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}